H-Prune through GSK-3β interaction sustains canonical WNT/β-catenin signaling enhancing cancer progression in NSCLC.
H-Prune through GSK-3β interaction sustains canonical WNT/β-catenin signaling enhancing cancer progression in NSCLC.
复制标题
DOI:
10.18632/oncotarget.2169
复制
发表时间:
2014-07-30
期刊:
影响因子:
--
通讯作者:
Zollo M
中科院分区:
文献类型:
--
作者:
Carotenuto M;De Antonellis P;Liguori L;Benvenuto G;Magliulo D;Alonzi A;Turino C;Attanasio C;Damiani V;Bello AM;Vitiello F;Pasquinelli R;Terracciano L;Federico A;Fusco A;Freeman J;Dale TC;Decraene C;Chiappetta G;Piantedosi F;Calabrese C;Zollo M
H-Prune hydrolyzes short-chain polyphosphates (PPase activity) together with an hitherto cAMP-phosphodiesterase (PDE), the latest influencing different human cancers by its overexpression. H-Prune promotes cell migration in cooperation with glycogen synthase kinase-3 (Gsk-3β). Gsk-3β is a negative regulator of canonical WNT/β-catenin signaling. Here, we investigate the role of Gsk-3β/h-Prune complex in the regulation of WNT/β-catenin signaling, demonstrating the h-Prune capability to activate WNT signaling also in a paracrine manner, through Wnt3a secretion. In vivo study demonstrates that h-Prune silencing inhibits lung metastasis formation, increasing mouse survival. We assessed h-Prune levels in peripheral blood of lung cancer patients using ELISA assay, showing that h-Prune is an early diagnostic marker for lung cancer. Our study dissects out the mechanism of action of h-Prune in tumorigenic cells and also sheds light on the identification of a new therapeutic target in non-small-cell lung cancer.